32 results
424B5
vkofp
24 Mar 22
Prospectus supplement for primary offering
4:15pm
PRE 14A
hl0hnt80
1 Sep 21
Preliminary proxy
4:46pm
424B5
wbrisb46v93g565nfp8
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-10.1
vcjlcrbxawdl0eexpehs
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
cjyodptf q9ba
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
424B3
0loy03by9rnsc
12 Apr 21
Prospectus supplement
1:44pm
S-3
ks0dsl18qqms
2 Apr 21
Shelf registration
12:00am